CN108998519A - Predict the biomarker long-chain non-coding RNA LINC02413 and kit of colon cancer prognosis - Google Patents
Predict the biomarker long-chain non-coding RNA LINC02413 and kit of colon cancer prognosis Download PDFInfo
- Publication number
- CN108998519A CN108998519A CN201810804937.2A CN201810804937A CN108998519A CN 108998519 A CN108998519 A CN 108998519A CN 201810804937 A CN201810804937 A CN 201810804937A CN 108998519 A CN108998519 A CN 108998519A
- Authority
- CN
- China
- Prior art keywords
- linc02413
- colon cancer
- real
- predicting
- prognosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention provides a kind of biomarker long-chain non-coding RNA LINC02413 and kit for predicting colon cancer prognosis, for predicting colorectal cancer patients prognosis life cycle.The preparation for predicting colon cancer prognosis is real-time fluorescence quantitative PCR detection kit, real-time fluorescence quantitative PCR detection kit includes the specific primer of the specific primer and reference gene TUBA1A expression for testing goal gene LINC02413 expression, also includes real time fluorescent quantitative SYBR dyestuff, the water without RNA enzyme.The present invention is related with the survival rate of patient by quantitative fluorescent PCR and the survivorship curve analysis LINC02413 for finding colon cancer tissue source, and content is higher, and survival rate is higher.This method helps to improve the postoperative life quality of colorectal cancer patients, works out aftertreatment scheme, improve survival rate, have far-reaching clinical meaning to predict that the prognosis life cycle analysis of colorectal cancer patients provides strong technical support.
Description
Technical field
The invention belongs to biomedicine technical fields, and in particular to the non-volume of biomarker long-chain of prediction colon cancer prognosis
Code RNA LINC02413 and kit.
Background technique
Colon cancer refers to the malignant change that mucous membrane of colon epithelium occurs under a variety of carcinogenic factor effects such as environment or heredity.
It is common one of malignant tumour.Its disease incidence is high, and its morbidity and mortality is still in ascendant trend.Colon cancer so far
Treatment can not show a candle to people's will early for early discovery, early diagnosis.Because of unobvious and specificity early clinic symptom, it is not easy to be found,
Therefore Misdiagnosis situation is extremely serious, most of patients needs correctly diagnose for a long time, so that quite a lot of patient loses healing machine
Meeting.Colorectal cancer is located at the third position of tumor incidence, is located at the second of whole tumor incidences, the death rate in urban area
Account for the 4th of whole malignant tumours.Operation excision at present is still the primary treatment measure of colorectal cancer patients long term survival, but big
The main reason for most destiny for being finally still unable to escape relapse and metastasis, the recurrence and transfer of tumour are still death.Currently, facing
On bed not yet ideal molecular indexes come the risk assessing prognosis and shift.Therefore, new prognosis biological marker is found
Object is current urgent problem.
Non-coding RNA refers in biological genome the not RNA of coding protein.According to the length of transcript, non-coding RNA
Can be by the rough two major classes that are divided into: one kind be small molecule non-coding RNA of the length less than 200 nucleotide.At present research compared with
It is more to have Microrna s, siRNA and with the RNA (piRNA) of piwi albumen phase separation etc., mediate gene heavy in vivo
Silent, participation RNA shearing and protein modification, the transcription and translation of finely regulating gene etc.；The another kind of long-chain for being greater than 200nt
Non-coding RNAs occupy sizable ratio in non-coding RNA.Long-chain non-coding RNAs are previously considered to be genome
Noise is transcribed, some researches show that it in recent years reconstructs in chromatin, transcriptional control, transcription post-processing, protein metabolism etc.
There is important role.Long-chain non-coding RNA is classified long-chain non-coding RNAs, is a kind of functional RNA, conservative generally compared with
It is low.A large number of studies show that expression of the long-chain non-coding RNAs in genome has apparent Space-time speciality and organizing specific
Property, content increases with the increase of species complexity.Long-chain non-coding RNA in genome extensive functional group at packet
It includes in dyeing body dynamics, telomere and a series of effects in subcellular structure tissue etc..Studies have shown that gene regulation is permitted
More basic processes have the tune such as wide participation of long-chain non-coding RNA, including chromatin modification, transcriptional control, post-transcriptional control
Section process.
LINC02413 is a kind of newfound non-coding RNA, and transcript length is greater than 200 nucleotide.Currently,
The important function that LINC02413 is played during normal cell development or tumor development is also in further research.
Whether LINC02413 can be used as the new tumor markers of one kind for predicting that colorectal cancer patients prognosis not yet has been reported that.Therefore,
We illustrate for the first time with LINC02413 is new colon carcinoma marker the feasibility for predicting patient's prognosis.
Summary of the invention
The purpose of the present invention is to provide a kind of biomarker long-chain non-coding RNAs for predicting colon cancer prognosis
LINC02413 and kit, for predicting colorectal cancer patients prognosis life cycle.
To achieve the above object, the present invention adopts the following technical scheme: the biomarker of prediction colon cancer prognosis is
Long-chain non-coding RNA LINC02413, the nucleic acid sequence of long-chain non-coding RNA LINC02413 is as shown in SEQ NO:1.
Application of the long-chain non-coding RNA LINC02413 biomarker in the preparation of preparation prediction colon cancer prognosis.
The preparation of the prediction colon cancer prognosis is real-time fluorescence quantitative PCR detection kit.
For predicting the real-time fluorescence quantitative PCR detection kit of colon cancer prognosis, comprising being used for testing goal gene
The specific primer of LINC02413 expression, primer sequence are SEQ NO:2 and SEQ NO:3.
For predicting that the real-time fluorescence quantitative PCR detection kit of colon cancer prognosis includes reference gene TUBA1A expression
Specific primer, primer sequence are SEQ NO:4 and SEQ NO:5.
For predicting that the real-time fluorescence quantitative PCR detection kit of colon cancer prognosis is contaminated comprising real time fluorescent quantitative SYBR
Material, the water without RNA enzyme.
Real time fluorescent quantitative SYBR dyestuff in real-time fluorescence quantitative PCR detection kit for predicting colon cancer prognosis,
Target gene LINC02413 specific primer, reference gene TUBA1A specific primer, water without RNA enzyme volume ratio be 10:
1:1:6。
The beneficial effects of the present invention are: the present invention has found colon cancer group by quantitative fluorescent PCR and survivorship curve analysis
The LINC02413 for knitting source is related to the survival rate of patient, and content is higher, and survival rate is higher.This method is prediction colorectal cancer patients
Prognosis life cycle analysis provide strong technical support, help to improve the postoperative life quality of colorectal cancer patients, make
Aftertreatment scheme is ordered, survival rate is improved, there is far-reaching clinical meaning.
Detailed description of the invention
Fig. 1 is that real-time fluorescence quantitative PCR analyzes differential expression of the LINC02413 in normal tissue and colon cancer.
The prognosis of the LINC02413 expression height to colorectal cancer patients in the tracing analysis colon cancer tissue source for survival Fig. 2
It influences.
Specific embodiment
Present invention will be further explained below with reference to the attached drawings and specific embodiments.
Embodiment 1
The biomarker for predicting colon cancer prognosis is long-chain non-coding RNA LINC02413, the long-chain non-coding RNA
The nucleic acid sequence of LINC02413 is as shown in SEQ NO:1.
The preparation for predicting colon cancer prognosis is real-time fluorescence quantitative PCR detection kit, real-time fluorescence quantitative PCR detection examination
Agent box includes the specific primer expressed for testing goal gene LINC02413, primer sequence such as SEQ NO:2 and SEQ
Shown in NO:3, real-time fluorescence quantitative PCR detection kit includes the specific primer of reference gene TUBA1A expression, primer sequence
As shown in SEQ NO:4 and SEQ NO:5.
The reagent of preparation detection LINC02413 expression quantity is used to prepare the kit of colorectal cancer patients prognosis (for 50 times
Reaction), required reagent includes: that 500 μ L of SYBR Green qPCR Mix, 3 μM of target gene LINC02413 specificity are drawn
50 μ L of object, 3 μM of 50 μ L of reference gene TUBA1A specific primer, the 300 μ L of water without RNA enzyme.
The extracted total RNA agents useful for same from the tumour of colon cancer or normal control tissue, comprising: Trizol l20mL, suppression
RNA degradation solvent 40mL, chloroform 80mL, isopropanol 80mL, DEPC water 10mL processed.
It by LINC02413 reverse transcription is cDNA agents useful for same by template of total serum IgE, comprising: 10 × random primer and Oligo
100 μ L of mixture, 5 × reverse transcription reaction buffer, 150 μ L, the 10mM of dT primer contain Mg2+Triphosphoric acid base deoxynucleotide
100 μ L of dNTP, 50 μ L of 200U/ μ L M-MLV reverse transcriptase.
Embodiment 2
The detection of tissue samples LINC02413
1, colon cancer tumours tissue or normal control tissue to be measured are collected, after physiological saline cleans up, is put into and fills inhibition RNA
It degrades in the cryopreservation tube of solvent, puts spare to -80 DEG C of refrigerators.
2, the extracting of RNA in organizing
(1) liquid nitrogen is first added in mortar, then tissue is cut into small pieces and is clayed into power in liquid nitrogen, taken with the spoon of Liquid nitrogen precooler
100mg organizes powder to be added in the EP pipe for the Trizol liquid for having filled 1ml.Organize total powder volume no more than Trizol used
The 10% of volume is sufficiently mixed uniformly.
(2) 5 minutes are placed at room temperature for, the chloroform of 200 μ L is then added, EP is covered tightly and manages and acutely sway 0.5 minute.12000
Rev/min centrifugation 10 minutes.
(3) it takes upper strata aqueous phase in a new EP pipe, 500 μ L isopropanols is added, are mildly mixed by inversion.It is placed at room temperature for 10 points
Clock, 12000 revs/min are centrifuged 10 minutes.
(4) liquid is carefully discarded supernatant, 75% ethyl alcohol of 1ml is added, is vortexed and mixes, 12000 revs/min of centrifugations 5 at 4 DEG C
Minute.Repetitive operation is primary.
(5) liquid is discarded supernatant, room temperature or vacuum drying 5~10 minutes.RNA is dissolved with 50 μ L DEPC processed water.
(6) RNA concentration mensuration: being measured with nucleic acid concentration analyzer, is inhaled 1 μ L RNA sample and is added to sample well, according to
Reading directly determines the concentration of RNA.The OD260/OD280 ratio of the measurement of nucleic acid concentration analyzer, ratio is between 1.8-2.0
Think that RNA purity is fine.Finally, to be stored in -80 DEG C of refrigerators spare by RNA.
3, the reverse transcription of LINC02413 RNA
Use the Reverse Transcriptase kit (D7170S) of the green skies Bioisystech Co., Ltd in Shanghai.Specific step is as follows:
(1) it removes genomic DNA: template Total RNA, 5 × gDNA Eraser Buffer is thawed on ice, 5 × RT
Buffer, 10 × RT Primer Mix, DEPC-treated Water thaw at (15-25 DEG C) of room temperature, are immediately placed in after defrosting
On ice.Every kind of solution is mixed before use and of short duration centrifugation is so that all liq is settled down to tube bottom.The denaturation of RNA, RNA sample
Product after thermal denaturation 5 minutes, are immediately placed in ice water cooling under the conditions of 65 DEG C.According to the form below ingredient is in the mixing of preparation reaction on ice
Then liquid is dispensed into each reaction tube again, is eventually adding RNA sample.Reaction system and condition are as shown in table 1.
Table 1
(2) in PCR instrument or in water-bath, 37 DEG C are incubated for 2 minutes.Be immediately placed in place on ice it is spare.
(3) reverse transcription system is prepared: being carried out reaction solution preparation on ice, is carried out reverse transcription reaction immediately after soft mixing.
Mixed liquor is prepared according to the reverse transcription reaction system of following table.Reaction system and condition are as shown in table 2.
Table 2
(4) 42 DEG C are incubated for 60 minutes to carry out reverse transcription reaction, and subsequent 80 DEG C of incubations are put in for 10 minutes after inactivation reverse transcriptase
On ice.Reverse transcription temperature can be improved to 50 DEG C, to enhance reverse transcription effect in complicated for secondary structure or high GC content template
Rate.
(5) cDNA obtained can immediately or -80 DEG C freeze after for subsequent real-time fluorescence quantitative PCR, cDNA was preferably avoided
More multigelations.
4, real-time quantitative PCR is carried out using the specific primer of LINC02413
Specific primer is synthesized in Sangon Biotech (Shanghai) Co., Ltd., including for detecting LINC02413 expression
Specific primer, primer sequence is the specific primer that SEQ NO:2 and SEQ NO:3 and reference gene TUBA1A are expressed,
Primer sequence is SEQ NO:4 and SEQ NO:5.The other reagents of real-time quantitative PCR utilize the green limited public affairs of skies biotechnology in Shanghai
The BeyoFast SYBR Green qPCR Mix (2 ×) of department, the specific steps are as follows:
(1) various solution needed for melting and mixing PCR reaction, BeyoFast SYBR Green qPCR Mix melt completely
And it mixes and is placed in ice chest.
(2) PCR reaction system (by taking 96 orifice plates as an example) are set on ice bath, reaction system and condition are as shown in table 3.
Table 3
(3) the usually amount of DNA profiling with 1-10ng cDNA is with reference to dosage, and final concentration of 0.2-0.5 μM of primer when can be obtained
Good detection effect is obtained, the final concentration of primer can also be according to circumstances adjusted.If it is necessary, gradient dilution can be carried out to template,
With the optimal template usage amount of determination.When the cDNA that reverse transcription PCR reacts is directly as template, additive amount is not exceeded
PCR reacts the 10% of total volume.The recommendation response system of 96 orifice plates is 20 μ l, can also be expanded in proportion according to actual experiment demand
Big or diminution reaction system.
(4) mixing is gently blown and beaten with pipettor or slight Vortex is mixed, and room temperature is centrifuged the several seconds, and liquid is made to accumulate in pipe
Bottom.
(5) the PCR reaction tube set or PCR reaction plate are placed on fluorescence quantitative PCR instrument, start PCR reaction.
(6) PCR response procedures: the initial denaturation of template is carried out before real-time fluorescence quantitative PCR reacts, is typically set at 95 DEG C
2 minutes.Using following PCR program, this program is by taking ABI 7900HT fluorescence quantitative PCR instrument as an example: a. initial denaturation: 95 DEG C
2min；B. it is denaturalized: 95 DEG C of 15sec；C. annealing/extension: 60 DEG C of 15-30sec；D. step b and step c is repeated, in total
40 circulations；E. melting curve analysis (optional): 95 DEG C of 15sec, 60 DEG C of 15sec, 95 DEG C of 15sec；F. using glimmering
The software that Fluorescent Quantitative PCR instrument provides analyzes result.Three-step approach need to only add 72 DEG C of 30sec of a step after annealing/extension, then weight
Multiple step b, c and it is increased the step for totally 40 circulations.
5, the data analysis of LINC02413 expression quantity
This experimental data is included in 60 colorectal cancer patients and its normal control tissue.The interpretation of result of real-time quantitative PCR uses phase
To quantitative approach, that is, 2^-△△CtMethod.It is specific as follows: firstly, all gene C t values that will once test are put in order, later with each
The Ct value of target gene LINC02413 in group tumor sample subtracts the Ct value of itself reference gene TUBA1A, and obtained number is just
It is △ Ct；Changing formula into is exactly: △ Ct=Ct(target gene LINC02413)-Ct(reference gene TUBA1A)；It then, will be each
The △ Ct of group each target gene of tumor sample LINC02413 is calculated.With the △ Ct of tumor tissues sample in this experiment
The △ Ct of normal control tissue group sample is subtracted, and opposite number is taken to all results simultaneously, the result which obtains is exactly-
△△Ct.Finally, p- △ △ Ct carries out 2 power operation, i.e. 2^-△△CtJust show that the multiple of expression quantity changes.In triplicate, sharp
It is examined with nonparametric t- for statistical analysis.As a result as shown in Figure 1, in the tumor tissues of colon cancer LINC02413 expression quantity
It is higher than normal control tissue, difference have statistical difference (p< 0.05).
By 60 colorectal cancer patients follow-up statistics being included in above-mentioned experiment, including patient's First episode when
Between, treatment condition, recurrence status and death time etc., follow up time is at least 12 months.In selected colorectal cancer patients,
The expression value for choosing fluorescence real-time quantitative PCR analysis is reference standard, and the corresponding normal tissue of acquired results compares, and is tied
Fruit is as shown in Figure 2.The patient that LINC02413 expression is higher than normal control tissue in tumor tissues is defined as LINC02413 high table
Up to group, remaining is low expression group.By Kaplan-Meier survival analysis, LINC02413 high expresses the life cycle ratio of patient
The patient of LINC02413 low expression group is substantially reduced, and prognosis is worse, difference have it is statistically significant (p< 0.05).Therefore,
LINC02413 can be used as the specificity molecular marker of colorectal cancer patients prognosis.
The above is the preferred embodiment of the present invention, it is noted that for those skilled in the art, this hair
It is bright to be not restricted to the described embodiments, under the premise of not departing from general idea of the present invention, several variations can also be made and changed
Into these also should be considered as protection scope of the present invention.
SEQUENCE LISTING
<110>the first affiliated hospital of Zhengzhou University
<120>the biomarker long-chain non-coding RNA LINC02413 and kit of colon cancer prognosis are predicted
<130> 1
<160> 5
<170> PatentIn version 3.5
<210> 1
<211> 310
<212> DNA
<213>people
<400> 1
aattgcttga acgtgggagg cagagactgc agtgagccgg gttgtgtcac tgcactccag 60
cctgggcgac agagcgacag agtgagactc cttctcaaaa aaagaaagac taaatcaaag 120
taagaattca ctttgtactt tgctggaatt ttctattctg tagtcaatgg tggtttctag 180
tagtgcaggg tagggaaact ccagagccca actaaaataa ccacatgttc tgaagttaat 240
taaaagtata aattagtgtt ataaatagca agatgtccca ttcaatggtt ttaattattt 300
tacttctttg 310
<210> 2
<211> 20
<212> DNA
<213>artificial synthesized
<400> 2
cttgaacgtg ggaggcagag 20
<210> 3
<211> 20
<212> DNA
<213>artificial synthesized
<400> 3
tgggctctgg agtttcccta 20
<210> 4
<211> 20
<212> DNA
<213>artificial synthesized
<400> 4
cctgtcatgg cttctctggg 20
<210> 5
<211> 20
<212> DNA
<213>artificial synthesized
<400> 5
gggaagcagt gatggaggac 20
Claims (7)
1. the biomarker for predicting colon cancer prognosis is long-chain non-coding RNA LINC02413, the long-chain non-coding RNA
The nucleic acid sequence of LINC02413 is as shown in SEQ NO:1.
2. application of the biomarker as described in claim 1 in the preparation of preparation prediction colon cancer prognosis.
3. application as claimed in claim 2, it is characterised in that: the preparation of the prediction colon cancer prognosis is real time fluorescent quantitative
PCR detection kit.
4. for predicting the real-time fluorescence quantitative PCR detection kit of colon cancer prognosis, it is characterised in that: comprising for detecting mesh
Gene LINC02413 expression specific primer, primer sequence be SEQ NO:2 and SEQ NO:3.
5. as claimed in claim 4 for predicting the real-time fluorescence quantitative PCR detection kit of colon cancer prognosis, feature exists
In: the real-time fluorescence quantitative PCR detection kit includes the specific primer of reference gene TUBA1A expression, and primer sequence is
SEQ NO:4 and SEQ NO:5.
6. as claimed in claim 5 for predicting the real-time fluorescence quantitative PCR detection kit of colon cancer prognosis, feature exists
In: the kit includes real time fluorescent quantitative SYBR dyestuff, without the water of RNA enzyme.
7. as claimed in claim 6 for predicting the real-time fluorescence quantitative PCR detection kit of colon cancer prognosis, feature exists
In: real time fluorescent quantitative SYBR dyestuff, target gene LINC02413 specific primer, reference gene in the kit
TUBA1A specific primer, water without RNA enzyme volume ratio be 10:1:1:6.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810804937.2A CN108998519A (en) | 2018-07-20 | 2018-07-20 | Predict the biomarker long-chain non-coding RNA LINC02413 and kit of colon cancer prognosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810804937.2A CN108998519A (en) | 2018-07-20 | 2018-07-20 | Predict the biomarker long-chain non-coding RNA LINC02413 and kit of colon cancer prognosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108998519A true CN108998519A (en) | 2018-12-14 |
Family
ID=64596797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810804937.2A Withdrawn CN108998519A (en) | 2018-07-20 | 2018-07-20 | Predict the biomarker long-chain non-coding RNA LINC02413 and kit of colon cancer prognosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108998519A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111206094A (en) * | 2018-11-21 | 2020-05-29 | 内蒙古医科大学附属人民医院 | PiRNA biomarker for noninvasive early diagnosis of colorectal cancer and rectal cancer and detection kit |
-
2018
- 2018-07-20 CN CN201810804937.2A patent/CN108998519A/en not_active Withdrawn
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111206094A (en) * | 2018-11-21 | 2020-05-29 | 内蒙古医科大学附属人民医院 | PiRNA biomarker for noninvasive early diagnosis of colorectal cancer and rectal cancer and detection kit |
| CN111206094B (en) * | 2018-11-21 | 2024-01-19 | 北京大学肿瘤医院内蒙古医院(内蒙古医科大学附属肿瘤医院、内蒙古自治区肿瘤医院、内蒙古自治区癌症中心) | PiRNA biomarker for noninvasive early diagnosis of colorectal cancer and rectal cancer and detection kit |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sherwood et al. | Characteristics, properties, and potential applications of circulating cell-free dna in clinical diagnostics: a focus on transplantation | |
| Fritzsche et al. | Concomitant down-regulation of SPRY1 and SPRY2 in prostate carcinoma | |
| CN109097477B (en) | circRNA marker for breast cancer diagnosis and application thereof | |
| CN109182521B (en) | Application of circRNA as thyroid papillary carcinoma marker | |
| WO2016186987A1 (en) | Biomarker micrornas and method for determining tumor burden | |
| CN107519193B (en) | Molecular diagnostic marker for early stage esophageal squamous carcinoma and application thereof | |
| CN101921831A (en) | Rapid detection of BRCA (Breast Cancer) genic mutation | |
| CN108998519A (en) | Predict the biomarker long-chain non-coding RNA LINC02413 and kit of colon cancer prognosis | |
| CN108707664A (en) | A kind of cancer of pancreas prognosis molecule marker non-coding RNA Lnc-COX19-2 and its application | |
| CN109266742A (en) | Predict the biomarker long-chain non-coding RNA LINC02456 and kit of colon cancer prognosis | |
| CN108728547A (en) | Application, kit and the detection method of kidney prognosis novel molecular marker non-coding RNA LINC00158 | |
| CN108424965A (en) | A kind of cancer of pancreas prognosis molecule marker non-coding RNA Lnc-CRYBA4-23 and its application | |
| CN108753960A (en) | A kind of gastric cancer prognosis molecule marker non-coding RNA Lnc-DENR-2 and its application | |
| CN109022576A (en) | Predict the biomarker long-chain non-coding RNA LINC02447 and kit of colon cancer prognosis | |
| CN108424966A (en) | A kind of gastric cancer prognosis molecule marker non-coding RNA Lnc-CIT-1 and its application | |
| CN108998522A (en) | Predict the biomarker long-chain non-coding RNA LINC01725 and kit of colon cancer prognosis | |
| CN108998521A (en) | Predict the biomarker long-chain non-coding RNA LINC01728 and kit of colon cancer prognosis | |
| CN108977537A (en) | Predict the biomarker long-chain non-coding RNA LINC02327 and kit of colon cancer prognosis | |
| CN108546760A (en) | A kind of cancer of pancreas prognosis molecule marker non-coding RNA Lnc-COL20A1-2 and its application | |
| CN107937528B (en) | Glioma prognosis marker hsa _ circ _0125365 and application | |
| CN108753978A (en) | Application, kit and the detection method of lung cancer for prognosis novel molecular marker non-coding RNA LINC01124 | |
| CN108977536A (en) | Predict the biomarker long-chain non-coding RNA LINC01504 and kit of lung cancer for prognosis | |
| CN108998520A (en) | Predict the biomarker long-chain non-coding RNA LINC02372 and kit of colon cancer prognosis | |
| CN109022577A (en) | Predict the biomarker long-chain non-coding RNA LINC01366 and kit of lung cancer for prognosis | |
| CN109022578A (en) | Predict the biomarker long-chain non-coding RNA LINC01266 and kit of lung cancer for prognosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20181214 |